| value |
{"aggregator_url":"https://news.google {"aggregator_url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5Cc2hXbUItSXhSYWJ2UlQ4RDAtS045Q2MzUlNTV0pMalpOVXZGNzgtVmxINGdGcV9JT1V0eW5zTDZBZFM3eXBlcmRzTTlnR05CT28zOE5iVzVDOE93T3k4?oc=5","as_of":"2026-04-08T11:43:27.727928+00:00","canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAINAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2MABJgB0xD8Xegxuxy7eYXFqjyp-Q/m=syndicationarticleview,_b,_tp","enrichment":{"aggregator_url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5Cc2hXbUItSXhSYWJ2UlQ4RDAtS045Q2MzUlNTV0pMalpOVXZGNzgtVmxINGdGcV9JT1V0eW5zTDZBZFM3eXBlcmRzTTlnR05CT28zOE5iVzVDOE93T3k4?oc=5","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_78af5f54b3bb295b","canonical_host":"gstatic.com","canonical_is_aggregator":true,"canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAINAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2MABJgB0xD8Xegxuxy7eYXFqjyp-Q/m=syndicationarticleview,_b,_tp","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-08T11:44:28.227177+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5Cc2hXbUItSXhSYWJ2UlQ4RDAtS045Q2MzUlNTV0pMalpOVXZGNzgtVmxINGdGcV9JT1V0eW5zTDZBZFM3eXBlcmRzTTlnR05CT28zOE5iVzVDOE93T3k4?oc=5&hl=en-US&gl=US&ceid=US:en","html_truncated":true,"paywall_likely":false,"publisher_domain":"nature.com","publisher_resolution":"payload_source_domain","requested_url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5Cc2hXbUItSXhSYWJ2UlQ4RDAtS045Q2MzUlNTV0pMalpOVXZGNzgtVmxINGdGcV9JT1V0eW5zTDZBZFM3eXBlcmRzTTlnR05CT28zOE5iVzVDOE93T3k4?oc=5","source_event_id":"evt_3ecf63335c6e","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"ebb9e2c7f5615da0","published_at":"2026-04-08T01:08:37+00:00","publisher_domain":"nature.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.66,"dates_mentioned":[],"entities":[{"asset_class":"other","name":"Setidegrasib","relevance":"high","symbol":"","type":"drug"},{"asset_class":"other","name":"KRAS p.G12D","relevance":"high","symbol":"","type":"genetic_mutation"},{"asset_class":"other","name":"Advanced NSCLC","relevance":"high","symbol":"","type":"disease_stage"},{"asset_class":"other","name":"Pancreatic cancer","relevance":"high","symbol":"","type":"disease"},{"asset_class":"other","name":"Florida Cancer Specialists & Research Institute","relevance":"medium","symbol":"","type":"organization"},{"asset_class":"other","name":"Phase 1 study","relevance":"medium","symbol":"","type":"clinical_trial_phase"},{"asset_class":"other","name":"Nature","relevance":"medium","symbol":"","type":"publisher"}],"event_type":"research","information_gaps":["No specific trial identifiers (e.g., NCT number), enrollment size, dosing regimen, or endpoints are included in the provided text.","No quantitative efficacy (response rates, median duration of response, progression-free survival) or safety metrics are provided.","The excerpt does not confirm whether Nature\u2019s article is reporting new trial data vs. a general development update.","No timeline (e.g., expected readout dates) is included beyond the implication of near-term Phase 1 progress."],"key_facts":["The headline states that new drugs aim at one of cancer\u2019s deadliest mutations (KRAS p.G12D).","Setidegrasib is described as being in advanced NSCLC and pancreatic cancer with the KRAS p.G12D variant.","The provided source summary indicates Setidegrasib is first-in-class and KRAS-targeted.","A Phase 1 study is referenced as showing antitumor activity (exact magnitude not provided in the supplied text).","Florida Cancer Specialists & Research Institute is stated to contribute to the Phase 1 study."],"numeric_claims":[],"primary_claim":"Setidegrasib is being advanced as a first-in-class KRAS-targeted therapy for patients with advanced NSCLC and pancreatic cancer harboring the KRAS p.G12D variant.","relevance_score":0.62,"sentiment":"positive","source_quality":"high","summary":"Nature reports new cancer drugs targeting the KRAS p.G12D mutation, highlighting Setidegrasib\u2019s development in advanced NSCLC and pancreatic cancer. The signal points to early clinical progress as a near-term catalyst, but detailed efficacy/safety results are not present in the provided text.","topics":["oncology","KRAS targeting","precision medicine","clinical trials","NSCLC","pancreatic cancer","undruggable mutations"]},"source":"Nature","source_domain":"nature.com","source_url":"https://www.nature.com","summary":"New drugs take aim at one of cancer\u2019s deadliest mutations Nature Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant ascopost.com Breakthrough drugs could finally tackle deadliest \u2018undruggable\u2019 cancer mutation The News International Erika Hamilton on Advancing KRAS G12D Targeting in Lung and Pancreatic Cancer Oncodaily Florida Cancer Specialists & Research Institute Contributes to Phase 1 Study Demonstrating Antitumor Activity with First-in-Class KRAS-Targeted Therapy for Treatment of Lung and Pancreatic Cancers PR Newswire","title":"New drugs take aim at one of cancer\u2019s deadliest mutations - Nature","url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAINAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2MABJgB0xD8Xegxuxy7eYXFqjyp-Q/m=syndicationarticleview,_b,_tp"}... |